BioPharmSignal logoBioPharmSignal

Biotech News

Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids

Sight Sciences (SGHT)Sight SciencesCompany update

New direct practice expense supply code supports more consistent valuation of CPT 0563T MENLO PARK, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative,

Related news

SGHTSight Sciences2026-11-05 21:05 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

OTLKOutlook2026-10-01 13:01 EST

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

MGTXMeiraGTx2026-10-27 12:00 EST

MeiraGTx Announces Four Posters at the European Society of Gene and Cell Therapy (ESGCT) 2026 Annual Congress and the Network of Excellence for ALS (NEALS) Annual Meeting

PLSEPulse Biosciences2026-10-22 20:05 EST

Pulse Biosciences Schedules Third Quarter 2026 Financial Results Conference Call for November 5, 2026

ANGOAngioDynamics2026-10-21 12:30 EST

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

SENSSenseonics2026-10-21 12:00 EST

Senseonics Holdings, Inc. Schedules Third Quarter 2026 Earnings Release and Conference Call for November 9, 2026 at 4:30 P.M. Eastern Time

ANGOAngioDynamics2026-10-14 11:00 EST

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

IRIXIRIDEX2026-10-12 11:00 EST

Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma

PLSEPulse Biosciences2026-10-07 11:00 EST

Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation Treatment

View all latest news

Sight Sciences

Interventional Eye Care Sight Sciences develops minimally invasive and noninvasive technologies intended to address underlying causes of glaucoma and dry-eye disease. Glaucoma Systems OMNI and OMNI Edge are implant-free minimally invasive glaucoma-surgery systems that access Schlemm's canal and the trabecular meshwork. SION is a...

Recent company news

SGHTSight Sciences2026-11-05 21:05 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

SGHTSight Sciences2026-11-05 13:00 EST

Sight Sciences Announces CMS Establishment of a Practice Expense Supply Code for TearCare SmartLids

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

SGHTSight Sciences2026-10-01 11:05 EST

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

Stock data

Close
9.76 USD
Market cap
236.14M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States